| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/24/2023 | -15.79% | Morgan Stanley | $7 → $4 | Maintains | Underweight |
| 08/15/2022 | 47.37% | Morgan Stanley | $6 → $7 | Maintains | Underweight |
| 03/02/2022 | 68.42% | JP Morgan | $10 → $8 | Maintains | Neutral |
| 03/01/2022 | 89.47% | SVB Leerink | $10 → $9 | Maintains | Market Perform |
| 02/16/2022 | 110.53% | SVB Leerink | $11 → $10 | Maintains | Market Perform |
| 01/06/2022 | 47.37% | Morgan Stanley | $14 → $7 | Downgrades | Equal-Weight → Underweight |
| 11/18/2021 | 131.58% | SVB Leerink | → $11 | Downgrades | Outperform → Market Perform |
| 10/20/2021 | 321.05% | SVB Leerink | $60 → $20 | Maintains | Outperform |
| 10/20/2021 | 236.84% | JP Morgan | $61 → $16 | Downgrades | Overweight → Neutral |
| 10/05/2021 | 1057.89% | Morgan Stanley | → $55 | Downgrades | Overweight → Equal-Weight |
| 09/09/2021 | 1163.16% | SVB Leerink | → $60 | Initiates Coverage On | → Outperform |
| 08/18/2021 | 678.95% | Morgan Stanley | $35 → $37 | Maintains | Overweight |
| 06/03/2021 | 636.84% | Morgan Stanley | $82 → $35 | Maintains | Overweight |
| 04/06/2021 | 1626.32% | Morgan Stanley | $49 → $82 | Maintains | Overweight |
| 01/29/2021 | 1289.47% | JP Morgan | $45 → $66 | Maintains | Overweight |
| 11/25/2020 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 847.37% | JP Morgan | → $45 | Initiates Coverage On | → Overweight |
| 11/24/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 931.58% | Morgan Stanley | → $49 | Initiates Coverage On | → Overweight |
What is the target price for Atea Pharmaceuticals (AVIR)?
There is no price target for Atea Pharmaceuticals
What is the most recent analyst rating for Atea Pharmaceuticals (AVIR)?
There is no analyst for Atea Pharmaceuticals
When is the next analyst rating going to be posted or updated for Atea Pharmaceuticals (AVIR)?
There is no next analyst rating for Atea Pharmaceuticals
Is the Analyst Rating Atea Pharmaceuticals (AVIR) correct?
There is no next analyst rating for Atea Pharmaceuticals